Live Breaking News & Updates on Neuromyelitis Optica Spectrum

Stay updated with breaking news from Neuromyelitis optica spectrum. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Roche to present data across broad and impactful neuroscience portfolio at 2022 AAN Annual Meeting

Maximally sustaining IL-6 suppression in a chronic disease like NMOSD and enabling subcutaneous dosing every four weeks. Positive Phase III results for ENSPRYNG, as both monotherapy and in. | March 25, 2022 ....

United States , South Korea , Nathalie Meetz , Levi Garraway , Loren Kalm , Impact Of Administration Ocrelizumab , Sclerosis Care Center , Drug Administration , Head Of Global Product Development , Risdiplam Clinical Trial Development Program , European Union , Roche Group , American Academy Of Neurology , European Medicines Agency , Roche Group Media Relations , American Academy , Annual Meeting , Chief Medical Officer , Global Product , Suboptimal Response , Prior Disease Modifying Therapies , Year Data , Year Interim Results , Term Suppression , Regional Volume Loss , Label Extension ,

F. Hoffmann-La Roche Ltd: Roche to present data across broad and impactful neuroscience portfolio at 2022 AAN Annual Meeting

First data showing OCREVUS treatment effect on disability progression in non-active secondary progressive multiple sclerosis and further data in primary progressive MS will be presentedEvrysdi data continue ....

United States , South Korea , Nathalie Meetz , Levi Garraway , Karl Mahler , Sabine Borngr , Gerard Tobin , Bruno Eschli , Birgit Masjost , Loren Kalm , Impact Of Administration Ocrelizumab , Sclerosis Care Center , Drug Administration , Head Of Global Product Development , Risdiplam Clinical Trial Development Program , European Union , Roche Group , American Academy Of Neurology , European Medicines Agency , Roche Group Media Relations , American Academy , Annual Meeting , Chief Medical Officer , Global Product , Suboptimal Response , Prior Disease Modifying Therapies ,

Horizon Therapeutics plc: New Analysis of UPLIZNA (inebilizumab-cdon) for Neuromyelitis Optica Spectrum Disorder (NMOSD) Published in Neurology Neuroimmunology & Neuroinflammation

Horizon Therapeutics plc: New Analysis of UPLIZNA (inebilizumab-cdon) for Neuromyelitis Optica Spectrum Disorder (NMOSD) Published in Neurology Neuroimmunology & Neuroinflammation
published in the
Annals of Neurology assesses a potential new biomarker for NMOSD attack risk, severity and treatment effects
Horizon Therapeutics plc (Nasdaq: HZNP) today announced the publication of a new analysis of the pivotal Phase 2/3 N-MOmentum trial for UPLIZNA (inebilizumab-cdon), assessing the potential for reduced risk of worsening disability in those living with NMOSD. These data are published in the May issue of
Neurology Neuroimmunology Neuroinflammation. UPLIZNA is the first and only FDA-approved anti-CD19 B-cell depleting humanized monoclonal antibody for the treatment of adult patients with anti-aquaporin-4 (AQP4) antibody positive NMOSD. ....

Quinn Dinh , Ruth Venning , A Neuromyelitis Optica , Ray Gordon , Neuroimmunol Neuroinflamm , Tina Ventura , Neuroimmunology Neuroinflammation , Rachel Vann , Product Communications , Neurology Neuroimmunology , Hepatitisb Virus , Progressive Multifocal Leukoencephalopathy , Prescribing Information , Neuromyelitis Optica Spectrum Disorder , Neuromyelitis Optica Spectrum , Neurol Neuroimmunol , Glial Fibrillary Acidic Protein , Vice President , Investor Relations , Media Contact , ராய் கோர்டந் , டினா வென்ச்சுரா , ரேச்சல் வேன் , ப்ராடக்ட் தகவல்தொடர்புகள் , ப்ரிஸ்க்ரைபிஂக் தகவல் , துணை ப்ரெஸிடெஂட் ,

Investegate |Prothena Corporation plc Announcements | Prothena Corporation plc: Prothena Announces Appointment of Hideki Garren, MD, PhD, as Chief Medical Officer

Investegate |Prothena Corporation plc Announcements | Prothena Corporation plc: Prothena Announces Appointment of Hideki Garren, MD, PhD, as Chief Medical Officer
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.

Stanford University , United States , California Institute Of Technology , Los Angeles , Ellen Rose , Jennifer Zibuda , Hideki Garren , Roche Neuroimmunology , Novartis Pharma , Roche Ltd , University Of California , Head Of Communications , Investor Relations Communications , Roche Genentech Inc , Bayhill Therapeutics Inc , Prothena Corporation , Prothena Announces Appointment , Chief Medical , Gene Kinney , Chief Executive , Vice President , Global Head , Multiple Sclerosis , Neuromyelitis Optica Spectrum , Executive Director , Translational Medicine Expert ,

Prothena Announces Appointment of Hideki Garren, MD, PhD, as Chief Medical Officer

Share:
DUBLIN, Ireland, April 05, 2021 (GLOBE NEWSWIRE) Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid and neurodegenerative diseases, today announced the appointment of Hideki Garren, MD, PhD, as Chief Medical Officer. Dr. Garren will lead the clinical and medical organizations to advance Prothena s clinical pipeline.
Hideki brings valuable experience and expertise to our team as we look ahead towards transitioning to a fully integrated research, development and commercial biotechnology company, said Gene Kinney, PhD, President and Chief Executive Officer. His experience leading several late-stage development programs in neurology and rare disease indications through registration and launch is particularly relevant as we advance our pipeline of programs in these areas. We are delighted to welcome him to the team as we prepare for ....

Stanford University , United States , California Institute Of Technology , Los Angeles , Ellen Rose , Hideki Garren , Jennifer Zibuda , Roche Neuroimmunology , Novartis Pharma , University Of California , Roche Ltd , Head Of Communications , Investor Relations Communications , Roche Genentech Inc , Bayhill Therapeutics Inc , Prothena Corporation , Chief Medical , Gene Kinney , Chief Executive , Vice President , Global Head , Multiple Sclerosis , Neuromyelitis Optica Spectrum , Executive Director , Translational Medicine Expert , Executive Vice President ,